CoChat

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

Open access
Munster, Pamela, Krop, Ian E., LoRusso, Patricia, Ma, Cynthia, Siegel, Barry A., Shields, Anthony F., Molnár, István, Wickham, Thomas J., Reynolds, Joseph, Campbell, Karen, Hendriks, Bart S., Adiwijaya, Bambang S., Geretti, Elena, Moyo, Victor, Miller, Kathy D. · 2018 · British Journal of Cancer
Cited by 136

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

This phase 1 dose-escalation trial studied MM-302, a novel HER2-targeted PEGylated antibody–liposomal doxorubicin conjugate, in HER2-positive locally advanced/metastatic breast cancer. Patients were enrolled in four cohorts: MM-302 monotherapy (8, 16, 30, 40, and 50 mg/m 2 every 4 weeks [q4w]); MM-302 (30 or 40 mg/m 2 q4w) plus trastuzumab (4 mg/kg q2w); MM-302 (30 mg/m 2 ) plus trastuzumab (6 mg/kg) q3w; MM-302 (30 mg/m 2 ) plus trastuzumab (6 mg/kg) and cyclophosphamide (450 mg/m 2 ) q3w. Sixty-nine patients were treated. The most common adverse events (AEs) were fatigue and nausea. Grade 3/4 AEs of special interest included neutropenia, fatigue, mucosal inflammation, anemia, thrombocytopenia, febrile neutropenia, and palmar-plantar erythrodysesthesia. The MTD was not reached. With MM-302 ≥ 30 mg/m 2 , overall response rate (ORR) was 13% and median progression-free survival (mPFS) 7.4 months (95% CI: 3·5–10·9) in all arms. In 25 anthracycline-naïve patients, ORR was 28·0% and mPFS 10·9 months (95% CI: 1·8–15·3). Imaging with 64 Cu-labeled MM-302 visualized tumor-drug penetrance in tumors throughout the body, including the brain. MM-302 monotherapy, in combination with trastuzumab, or trastuzumab plus cyclophosphamide, was well tolerated and showed promising efficacy. The selected phase 2 MM-302 dose was 30 mg/m 2 plus 6 mg/kg trastuzumab q3w.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41416-018-0235-2

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 136

Metadata

Authors
Munster, P., Krop, I. E., LoRusso, P., Ma, C., Siegel, B. A., Shields, A. F., Molnár, I., Wickham, T. J., Reynolds, J., Campbell, K., Hendriks, B. S., Adiwijaya, B. S., Geretti, E., Moyo, V., & Miller, K. D.
Venue
British Journal of Cancer
Published
2018-10
Volume
119
Issue
9
Pages
1086-1093
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2896144504
Cited by
136
References
1
FWCI
3.79
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. https://app.cochat.ai/papers/10.1038/s41416-018-0235-2
The paper
Munster, P., Krop, I. E., LoRusso, P., Ma, C., Siegel, B. A., Shields, A. F., Molnár, I., Wickham, T. J., Reynolds, J., Campbell, K., Hendriks, B. S., Adiwijaya, B. S., Geretti, E., Moyo, V., & Miller, K. D. (2018). Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. British Journal of Cancer. https://doi.org/10.1038/s41416-018-0235-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.